Form 10Q
-----------
Revenue increased to $2.4 million for the three months ended March 31, 2006 compared to $2.0 million for the same period in 2005. The increase in revenue reflects higher research and development activities under our collaboration with Celladon and our recently initiated research and development activities under the NIH grant, partially offset by decreased research and development activities from our collaboration with IAVI. We expect that our revenue for the remainder of 2006 will consist primarily of research and development revenue earned under our collaborations with IAVI and Celladon and the contract from the NIH. For the next several years, our revenue will depend on the continuation of the current collaborations and our success with entering into and then performing under new collaborations.
http://biz.yahoo.com/e/060504/tgen10-q.html
Lo split 1:10 salverà dal delisting ma perdera appeal, troppo basso il circolante che rimarrà, credo che molti usciranno in un corso già in cerca di bottom.......
Come riportato nello stralcio non c'è d'aspettarsi niente di chè nel breve-medio, le cose + interessanti sono in fase2.....
Però rimango curioso come mai in tanti vi aspettate un rimbalzo